Meet Emerging Asian Life Science Innovators at Japan – Asia Life Science Showcase

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

We are excited to welcome back Kobe Biomedical Innovation Cluster (KBIC) as a Title Sponsor of RESI JPM 2027! Continuing our partnership, KBIC will once again bring together promising life science innovators from across Asia, connecting emerging technologies with the global investment and partnering community.  

As part of this collaboration, Japan – Asia Life Science Showcase will take place on January 11, 2027, from 1:00 – 3:00 PM at the San Francisco Marriott Marquis, during RESI JPM 2027.

This special two-hour showcase will feature eight innovative life science companies advancing technologies across oncology, regenerative medicine, cell therapy, infectious diseases, and medical technologies. From pioneering tooth regeneration therapies and next-generation cancer immunotherapies to engineered bacteriophages and brain-computer interfaces, these companies highlight the diversity and growing potential of Asia’s life science innovation ecosystem.

For investors, pharmaceutical companies, and business development professionals, this session offers an opportunity to discover emerging technologies and explore potential investment, licensing, and strategic partnership opportunities.

Meet the 8 Featured Companies

Toregem BioPharma Co., Ltd.  

Toregem BioPharma is developing a groundbreaking approach to tooth regeneration through its lead antibody candidate, TRG035, targeting USAG-1 to stimulate natural tooth development. Following Phase I clinical development, the company is advancing its program toward treating congenital tooth agenesis, with the potential to transform dental and regenerative medicine. 

Crafton Biotechnology Co., Ltd.  

Crafton Biotechnology is leveraging its proprietary PureCap® mRNA platform to develop next-generation therapeutics that enable sustained antibody production within the body. By potentially reducing treatment frequency and improving patient convenience, the company aims to address unmet medical needs in autoimmune and other chronic diseases. 

A-SEEDS Co., Ltd.  

A-SEEDS is advancing innovative CAR-T cell therapies targeting acute myeloid leukemia and solid tumors. Utilizing its proprietary non-viral piggyBac transposon platform, the company is developing durable, tumor-selective cell therapies designed to overcome key limitations of conventional CAR-T treatments. 

Arrowsmith Inc.  

Arrowsmith is harnessing synthetic biology to develop engineered bacteriophage therapies targeting antimicrobial-resistant infections. Its precision-based approach selectively eliminates harmful bacteria, including Pseudomonas aeruginosa, offering a potential alternative to conventional antibiotics in addressing the growing global antimicrobial resistance crisis. 

LIFESCAPES Inc. 

LIFESCAPES is developing non-invasive brain-computer interface (BCI) technology designed to restore hand movement in patients with severe paralysis resulting from stroke or spinal cord injury. By integrating brain signal monitoring, advanced software, and robotic assistance, its technology aims to improve rehabilitation outcomes and patients’ quality of life. 

Periotherapia Co., Ltd.  

Periotherapia is developing innovative antibody therapies targeting pathological periostin, a key component of the tumor microenvironment associated with treatment resistance. By disrupting protective barriers surrounding tumors, its approach aims to enhance drug penetration and improve the effectiveness of existing cancer therapies. 

CynosBio, Inc.  

CynosBio specializes in autologous cell therapies addressing unmet needs in ophthalmology and orthopedics. Its portfolio includes Sakracy, an approved regenerative therapy for severe ocular surface disorders in Japan, alongside a Phase III knee cartilage regeneration program, positioning the company for potential international clinical development and commercialization.

Mustbio Co., Ltd.  

Mustbio is advancing next-generation cancer immunotherapies through its proprietary multi-specific antibody platform. Its tri-specific fusion protein targets PD-1, VEGF, and IL-21 pathways to enhance anti-tumor immune responses and potentially overcome resistance to existing immunotherapies, particularly in patients with refractory or relapsed cancers.

Join Us at Japan – Asia Life Science Showcase during RESI JPM 2027! 

Date: Monday, January 11, 2027
Time: 1:00 – 3:00 PM (PST)
Location: San Francisco Marriott Marquis

RSVP for Japan – Asia Life Science Showcase

Whether you are an investor seeking promising early-stage opportunities, a pharmaceutical company exploring innovative technologies, or a business development professional looking to expand your network, Japan – Asia Life Science Showcase offers an opportunity to connect with emerging life science innovators from across Asia. 

Join us at RESI JPM 2027 to discover breakthrough technologies, meet innovative founders, and explore new opportunities for global collaboration! 

Register for RESI JPM 2027

RESI JPM 2027 Partnering Platform Launches Monday, November 16

By Karen Deyo, VP of Product, Israel BD, LSN

karen-wp

J.P. Morgan Healthcare Week is packed with satellite networking events, receptions, and pitch sessions competing for attention across San Francisco. Yet for early-stage life science startups, navigating the crowded hotel lobbies often results in fragmented conversations and low conversion rates.

When it comes to securing qualified capital and licensing discussions, RESI Partnering is the single most critical partnering platform of JPM Week.

Unlike general industry gatherings where early-stage founders are mixed in with late-stage and commercial companies, the RESI Partnering System is engineered specifically for Seed, Series A, and Series B innovators. With the platform officially going live on Monday, November 16, 2026, participants gain an immediate head start to connect directly with active decision-makers.

Why RESI Partnering Is the Most Critical Platform for Startups

The RESI system eliminates the guesswork of JPM Week by pairing deep matchmaking criteria with active capital allocators:

  • Targeted Investor Mandates: Filter investors not by generic categories, but by detailed investment criteria: indication, phase of development, modality, and capital structure preferences across Therapeutics, Medical Devices, Diagnostics, and Digital Health.
  • Verified, Active Checkbooks: Connect with over 700 active early-stage investors, venture funds, family offices, and corporate venture capital (CVC) scouts attending with explicit deployment mandates.
  • A Dedicated 5-Day Hybrid Structure: Lock in face-to-face meetings during the two in-person days in San Francisco (January 11 and 12), and continue building relationships through three dedicated virtual partnering days (January 13, 18, and 19) designed to fit around busy JPM schedules.
  • Two Full Months of Momentum: Early access starting November 16 ensures you can initiate dialogue, review incoming requests, and lock in your schedule long before arriving in San Francisco.

Free Live Webinar: RESI JPM Partnering Tutorial

To help attendees make the most of the software and maximize meeting acceptance rates, Life Science Nation is hosting a live, practical walkthrough on launch day:

  • Webinar: RESI JPM Partnering Tutorial
  • Date & Time: Monday, November 16, 2026 | 11:00 AM – 12:00 PM Eastern Time (US & Canada)
  • Registration: Sign Up for the Free Zoom Webinar

The LSN team will guide participants through advanced search filtering, best practices for writing high-converting meeting requests, follow-up strategies, and schedule management across both in-person and virtual sessions.

Learn how to craft compelling outreach messages and strategic follow-ups that drive engagement, secure high-priority meetings, and build lasting connections with potential partners and capital allocators: Watch LSN Event Partnering Process here.

Choosing Your Outreach Tier: Standard vs. Premier vs. Premier PLUS

Fundraising executives can align their partnering capabilities with their internal resources using three distinct tiers:

Features Standard
Base
Premier
+$750
PLUS
+$2,500
1-on-1 Partnering Access ✓ ✓ ✓
Investor Mandates & Profiles ✓ ✓ ✓
Direct Contact Info (Email/Phone) ✕ ✓ ✓
Granular Subsectors & Team Reqs ✕ ✓ ✓
Turnkey Outreach by LSN Team* ✕ ✕ ✓
*Limited Spots: Dedicated capacity is capped; Premier PLUS closes Nov 16.

Critical Milestone: Premier PLUS Closes on Launch Day (Nov 16)

Because Premier PLUS provides dedicated, hands-on campaign execution directly from LSN analysts, team capacity is strictly limited.

Registration for Premier PLUS will close on Monday, November 16, 2026.

  • New Registrants: Select Standard Partnering, add the Premier Package (+$750), or secure Premier PLUS (+$2,500) during checkout in the RESI JPM Registration Portal.
  • Already Registered for RESI JPM? Existing pass holders can add the Premier Package or claim one of the remaining Premier PLUS spots before November 16 by contacting the team directly at salescore@lifesciencenation.com.

Explore confirmed attending investors and event details at resiconference.com.

Register for RESI JPM & Add Premier Partnering

Why Most JPM Pitch Sessions Fail Early-Stage Startups, and How to Master Your Delivery at RESI JPM 2027

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

During J.P. Morgan Healthcare Week, presenting your technology in front of active capital allocators is one of the most effective ways to accelerate an early-stage fundraising campaign. For Seed, Series A, and Series B founders, a well-executed pitch can compress months of outreach into four days of high-velocity investor dialogue. 

However, the reality on the ground in San Francisco is that the quality of pitch events varies widely. 

The Reality of JPM Pitch Events: Why Quality Matters 

Every January, dozens of satellite pitch sessions, demo days, and presentation showcases compete for attention across downtown San Francisco. Unfortunately, many of these formats end up creating little tangible value for founders: 

  • The “Empty Room” Syndrome: Startups are placed into peripheral side-rooms where the audience consists mostly of fellow founders waiting for their turn, rather than genuine capital allocators with active checkbooks. 
  • One-Way Broadcasts: Conventional pitch sessions offer five to ten minutes of uninterrupted presentation time, after which founders simply walk off the stage. There is no dialogue, no live questioning, and no way to know whether the narrative resonated. 
  • The Follow-Up Void: Once a session ends, founders are left guessing which investors in the room were genuinely interested, leading to cold post-event follow-ups that rarely convert. 

For early-stage innovators who are investing significant capital and time to be in San Francisco, pitching cannot be a vanity exercise. It must deliver qualified access, real-time feedback, and direct partnering continuity. 

Why the RESI Innovator’s Pitch Challenge (IPC) Provides a Superior Model 

The Innovator’s Pitch Challenge (IPC) at RESI JPM 2027 was engineered specifically to solve the shortcomings of typical conference showcases. Held during the in-person days at the San Francisco Marriott Marquis (January 11 and 12), the IPC integrates presentation visibility with structured due diligence:

IPC Package Feature What Is Included Strategic Value for Founders
Two (2) Full Hybrid Passes Includes two standard passes covering 2 in-person days (Jan 11-12) and 3 virtual partnering days (Jan 13, 18, 19). $6,590 standard value: Full access to the 1-on-1 partnering platform, investor panels, and educational workshops.
Live Pitch & Real Q&A Present on stage to a dedicated panel of active healthcare investor judges, followed by interactive live Q&A. Eliminates one-way broadcasting and connects directly with active capital allocators deploying funds into your sector.
Investor Evaluation Sheet Receive a consolidated report compiled directly from judge scorecards and anonymous qualitative notes. Actionable intelligence on how institutional investors evaluate your science, team, and commercial roadmap.
Dedicated Exhibit & Poster* Reserved poster board space in the high-traffic Yerba Buena exhibition hall with free printing for one (1) poster*. A dedicated physical base camp for two full days to anchor spontaneous walk-up meetings and follow-up discussions.
*Note on Poster Printing: Free printing is provided for one (1) poster per participating company, provided that print-ready artwork is submitted prior to the designated printing deadline.

By combining live stage presentation with the official Investor Evaluation Sheet, IPC finalists receive invaluable data on how their scientific milestones, regulatory pathways, and commercial models are perceived by active decision-makers. 

Execution: How to Pitch to Investors and Handle Live Q&A 

Being selected for an investor pitch session is only the first step. The real differentiator between a polite response and a request for a follow-up meeting is how effectively you execute on stage. 

When presenting to institutional healthcare investors, founders must navigate two fundamental challenges: 

  • Translating Science into Commercial Milestones: Investors evaluate hundreds of assets during JPM Week. Your pitch must quickly articulate not just how your technology works, but how your next milestone materially de-risks the asset and creates a value inflection point. 
  • Mastering the Q&A Defense: The question-and-answer period is where investors test the depth of your leadership team. Whether responding to inquiries regarding regulatory flexibility, clinical trial design, competitive moats, or valuation expectations, your answers need to be direct, transparent, and grounded in data. 

To assist founders in refining their presentations, structuring compelling pitch narratives, and preparing for live investor inquiries, our team conducted a dedicated strategy session. You can review the complete discussion as you finalize your materials: 

[Webinar Recording] Pitching Strategy & Q&A Educational Session

Pitch slots across therapeutics, medical devices, diagnostics, and digital health tracks are strictly capped to ensure high judge-to-presenter ratios and dedicated evaluation time. The application deadline for the RESI JPM 2027 Innovator’s Pitch Challenge is Wednesday, November 11, 2026. Applications are reviewed and confirmed on a rolling basis, and sessions regularly fill before the final deadline. 

If you are raising capital and want to position your company directly in front of active buy-side investors during JPM Healthcare Week, secure your application today: 

Apply to Pitch at RESI JPM 2027

RESI JPM 2027 on Track to Surpass Last Year’s 850 Investors and Licensing Partners

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

More than 100 investors and licensing partners have already confirmed for RESI JPM 2027, and we are on pace to pass the 850 who attended last year

That number deserves a second look. Most conferences report total attendance, which is mostly other companies. 850 is the buy side alone: venture capital, corporate venture, family offices, angel groups, strategic investors, and pharma business development teams. People with mandates and checkbooks, in one room, during the one week of the year when the entire industry is already in San Francisco.

Meet the Confirmed Investors 

RESI JPM runs in person on January 11 and 12 at the San Francisco Marriott Marquis, with three additional days of virtual partnering on January 13, 18, and 19. It is LSN’s largest conference of the year.

Why Density Is the Product

The hard part of early-stage fundraising is not the pitch. It is access.

Institutional calendars during JPM Week are locked months in advance, and an early-stage company without an existing relationship generally cannot get on them. The companies that do well that week are the ones who were already in the conversation.

RESI was built to change the math. Instead of chasing a handful of meetings around the city, you walk into a room with hundreds of active investors and licensing partners and you select who you want to meet before you arrive.

What Is Coming to RESI JPM 2027

The confirmed group spans the full early-stage ecosystem: venture capital, corporate venture arms, family offices, angel groups, strategic investors, and pharma and medtech business development. Mandates cover therapeutics, diagnostics, medical technology, digital health, and platform technologies, across preclinical through Phase 2.

How to Get the Most Out of It

  • Partnering meetings. Our system lets you filter the investor audience by stage, indication, geography, and check size, then request meetings directly. You build your own schedule rather than hoping for a hallway encounter.
  • The Innovator’s Pitch Challenge. Present to a live investor panel, get scored feedback in front of the room, and put your company in front of people who are evaluating in real time. Applications close on Wednesday, November 11.
  • Three virtual partnering days. January 13, 18, and 19 extend your reach to investors who could not travel, including a large international contingent who partner with us remotely.

Register

Registration is open now, and the investor count is still climbing. The earlier you register, the earlier you can start requesting meetings against the confirmed list.

Register for RESI JPM 2027

RESI JPM 2027 Investor Panel Lineup Announced 

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Life Science Nation is pleased to announce the finalized investor panel lineup for RESI JPM 2027, taking place January 11 and 12 at the San Francisco Marriott Marquis during J.P. Morgan Healthcare Week.

The two day program features 14 investor sessions across therapeutics, medtech, diagnostics, digital health, platform technologies, strategic partnerships, and alternative sources of capital.

Monday, January 11

9:00 AM | Follow the Money [2027 Outlook & Trends]

Where Life Science & Healthcare Investors See Opportunity in 2027

Every year at JPM, one question sets the tone for the week: where is the capital going? Investors from across therapeutics, medtech, diagnostics, digital health, and tools take the stage to share what they are seeing in fundraising, valuations, and exit windows. They will discuss which sectors are attracting conviction, which are being left behind, and how their own priorities have shifted since last year. Whether you are raising, investing, or building, this is the read on the market you need before the deals begin.

10:00 AM | What Is Fundable Now: Therapeutics [Early Stage Therapeutics]

What Earns a Term Sheet from Early Stage Biotech Investors

Early stage therapeutics investors must weigh scientific promise against the risks of translating it into a viable treatment. Seed through Series A investors get candid about what earns their conviction: differentiated biology, convincing translational evidence, and a credible clinical development strategy. The discussion explores how investors assess target validation, competitive positioning, safety, and the experiments needed to reduce key development risks. Expect frank talk about what makes them lean in, what makes them pass, and how founders can make a compelling scientific and investment case for a therapeutic program.

11:00 AM | Backing the Next Medical Breakthrough [Medical Devices]

How Investors Evaluate Early Stage Device Innovation

Medical device companies face distinct investment hurdles, from proving technical feasibility to establishing a path to clinical adoption. This panel brings together medtech investors to discuss how they evaluate early stage opportunities across surgical technologies, robotics, monitoring, wearables, and home care. The conversation examines clinical need, regulatory strategy, reimbursement, usability, and the evidence required to support adoption. Hear what makes a device differentiated, how investors assess development and commercial risk, and which milestones strengthen the case for investment.

1:00 PM | Strategics at the Table [Strategics]

How Corporate Partners Decide When to Invest, Partner & Acquire

Strategic partners are shaping which technologies reach patients, and they are increasingly involved long before a company is ready to sell. Business development leaders from pharma and medtech join corporate venture investors to explain when they engage, what they need to see, and how they think about partnering, investing, and acquiring. Learn how to get on a strategic partner’s radar, what makes a startup stand out in a crowded pipeline, and how to build a relationship that lasts beyond a single deal.

2:00 PM | The First Believers [First Check Investors]

How the Earliest Backers Turn Life Science Ideas into Fundable Companies

Every great company has someone who said yes first. This panel gathers the earliest backers in life sciences: angels, seed funds, venture studios, foundations, and accelerators. They explain how they evaluate opportunities before substantial scientific or commercial validation, what they look for in a founding team, and what gives them the conviction to write the first check. The conversation covers company formation, initial experiments, and how early capital and hands on support help founders establish a credible development path. For founders at the very start, it is a candid map of the road from initial concept to the first funded development milestones.

3:00 PM | The Brain Trust [CNS / Neuro]

Investing Across Neuroscience & Psychiatry

Few areas of medicine combine such enormous unmet need with such complex investment challenges. This panel brings together investors in therapeutics, neuromodulation devices, digital biomarkers, and diagnostics to discuss what draws capital into neuroscience and psychiatry. Together they explore how advances in biology, technology, and clinical trial design can reopen areas once considered too difficult, and how founders across modalities can position themselves to attract investment.

4:00 PM | Patient Capital [Family Offices]

How Family Offices Are Investing Directly in Life Sciences

Family offices offer a distinct route to life science capital through direct investing, syndication with peers, and investment structures that can support longer time horizons. This session explores what draws private capital to highly technical opportunities, how family offices diligence science and technology, and what founders should know before approaching them. Panelists discuss how they structure investments, work with specialist co-investors, and assess follow-on needs. It is a practical look at how to earn the confidence of this diverse investor community.

Tuesday, January 12

9:00 AM | Investing in Longer, Healthier Lives [Longevity]

The Science and Technologies Addressing Age Related Disease

Helping people live longer, healthier lives requires addressing the diseases and functional challenges that come with aging. This panel brings together therapeutics, medtech, diagnostics, and digital health investors to explore opportunities in cardiometabolic disease, musculoskeletal health, physical function, and maintaining independence. The discussion examines how investors evaluate treatments for specific age related conditions alongside technologies that address underlying aging biology, detect risk earlier, or help people remain active. Hear what constitutes meaningful clinical evidence, how companies define a viable path to market, and what makes an opportunity compelling for early stage investment.

10:00 AM | Digital Health After the Hype [Digital Health]

What Investors Want to See in Evidence, Adoption & Economics

The digital health market has been through a reset. Investors discuss what they are backing now: clinical grade AI, new models of care delivery, and businesses with evidence, engagement, and economics that hold up to scrutiny. Hear where value is being created, what has changed in how these companies are evaluated, and what separates durable businesses from those that struggle to convert adoption into sustainable growth.

11:00 AM | Enabling the Next Generation of Medicine [Platform Technologies]

Investing in Discovery Platforms, Delivery Technologies & Research Tools

Some of the most valuable companies in life sciences make new medicines possible. This panel brings together investors backing AI enabled discovery platforms, delivery technologies, synthetic biology, and the research tools that accelerate development. The conversation centers on how to separate a durable platform from a clever technology, how investors evaluate platform companies alongside tools and infrastructure businesses, and how business models differ from those of asset driven companies. Hear what makes these technologies investable and where founders can build lasting value.

1:00 PM | Capital Across Borders [Cross Border Investors]

How International Investors Evaluate and Finance Life Science Companies

Cross border investment can expand a company’s funding options, but attracting international capital requires understanding how investors evaluate opportunities beyond their home markets. This panel brings together investors from different regions to discuss geographic mandates, due diligence, syndication, and the local presence or development plans they expect from companies abroad. Hear what makes a company attractive to overseas investors, how investors work with local co-investors, and how founders can build relationships that lead to cross border financing.

2:00 PM | Runway Without the Round [Beyond Venture Capital]

Financing the Next Milestone Beyond Conventional Venture Equity

A conventional venture round is not the only way to fund a company. This panel explores non dilutive grants, foundation funding, venture debt, royalty financing, strategic agreements, and government backed programs. Capital providers explain who qualifies, what stage or evidence their funding requires, how long the process takes, and what obligations or tradeoffs founders should understand. The discussion examines which sources are suitable for early stage companies and how they can complement equity financing. Hear how to match funding to a development milestone and extend runway without relying solely on another conventional venture round.

3:00 PM | From Seed to Series A

Building the Evidence and Investor Confidence for the Next Round

Securing seed funding is only the beginning. This panel brings together seed investors and Series A investors to explore how life science companies turn initial funding into a financeable next round. The discussion covers setting achievable milestones, demonstrating progress against the original investment thesis, identifying a lead investor, and building a syndicate. Across therapeutics, medtech, and digital health, panelists discuss how founders should align development plans, capital needs, and fundraising timelines. Hear how existing investors assess follow-on support, what new investors need to see, and how to address gaps that can leave promising companies between rounds.

4:00 PM | The Investor Reverse Pitch

Meet the Investors and Discover What They Want to Fund

To close the conference, the roles flip. Investors from across therapeutics, medtech, diagnostics, digital health, and tools take the stage to pitch their mandates: what they invest in, at which stage, with what check size, and what gets their attention. Investors deliver short presentations, followed by audience Q&A. Founders leave with a clear list of who to follow up with and how to approach them. It is a practical, high energy finish to two days of conversations.

Speaker Submissions

Life Science Nation is currently seeking qualified investors, corporate business development leaders, family office representatives, and other capital providers for speaker consideration. Submit a speaker application.

Submit a speaker application

RESI Boston 2026 Innovator’s Pitch Challenge Winners Announced 

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Life Science Nation is pleased to announce the winners of the RESI Boston 2026 Innovator’s Pitch Challenge, held during Biotech Week Boston.

Over the two days o RESI, more than 70 early stage life science companies presented their innovations to an audience of active investors, strategic partners, and industry leaders. Following the final round of pitches, the top three companies were recognized during lunch on day two:

1st Place 2nd Place 3rd Place
Synaptic Bio Orthonika Ironsides Medical
Synaptic Bio Orthonika Ironsides Medical

Congratulations to Synaptic Bio, Orthonika, Ironsides Medical, and every company that took the stage. The caliber of innovation, preparation, and investor engagement throughout the Challenge reflected the exciting work advancing across the global life science ecosystem.

Judges’ Picks Award Winners

In addition to the overall winners, Life Science Nation is proud to recognize the companies that received the highest evaluation scores from the investor judges in each Innovator’s Pitch Challenge session:

These companies stood out to the judging panels for the quality of their presentations and the potential of their technologies to address important unmet needs.

Apply to Pitch at RESI JPM 2027

Applications are now open for the Innovator’s Pitch Challenge at RESI JPM 2027, taking place in San Francisco on January 11 to 12, with virtual partnering January 13 and 18 to 19.

The Innovator’s Pitch Challenge gives early-stage companies the opportunity to present live to active life science investors, receive structured feedback, and build meaningful connections through RESI partnering.

Apply to the Innovator’s Pitch Challenge and secure your opportunity to pitch at RESI JPM.

Apply to Pitch at RESI JPM 2027

Meet the Investor Judges at RESI Boston 2026 

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

RESI Boston brings together early-stage life science innovators and active investors during Biotech Week Boston. Life Science Nation is pleased to announce the investor judges participating in the Innovator’s Pitch Challenge (IPC).

This year’s IPC will feature more than 70 companies presenting across 20 pitch sessions over two days, offering startups a valuable opportunity to gain visibility, present directly to investors, and receive real-time feedback from experienced decision-makers.

Each pitch session will be evaluated by a panel of investor and strategic partner judges with expertise spanning therapeutics, medical devices, diagnostics, digital health, and life science tools. Companies will deliver a six-minute presentation followed by seven minutes of live investor Q&A, giving judges the opportunity to assess scientific differentiation, commercial potential, and investment readiness.

All IPC companies will also have a dedicated space in the RESI Exhibition Hall, creating additional opportunities for follow-up conversations and deeper engagement with investors and conference attendees.

RESI Boston attendees will be invited to vote with their RESI Cash for their favorite presenting companies. The Top 3 companies will be announced, with winners receiving prizes and additional exposure through the LSN Newsletter.

See the investors serving as judges for this year’s RESI Boston Innovator’s Pitch Challenge:

Featured RESI Boston IPC Judge
René Bastón
René Bastón
Covenant Venture Capital
Caleb Bell
Caleb Bell
Beyond Next Ventures
Randy Berholtz
Randy Berholtz
Mesa Verde Venture Partners
Shailesh Chavan
Shailesh Chavan
Ingenious Global Venture Partners
Bruce Cohen
Bruce Cohen
Xeraya Capital
Yvette Ferreira
Yvette Ferreira
Xcellerant Ventures
Navin Govind
Navin Govind
Evidence Ventures
Ole Henrik Bang Andreasen
Ole Henrik Bang Andreasen
Avant Bio
Christopher Hupp
Christopher Hupp
Ipsen S.A.
Deepak Jha
Deepak Jha
Autobahn Labs
James Lee
James Lee
Unistone Ventures
Claire Leurent
Claire Leurent
AbbVie Ventures
Heather Loring
Heather Loring
AstraZeneca
James Massaquoi
James Massaquoi
Glasswing Ventures
Mahesh Narayanan
Mahesh Narayanan
Neuvation Ventures
John Pennett
John Pennett
Mid Atlantic Bio Angels
Garrett Peterson
Garrett Peterson
Yahara Ventures
Andrew Rae
Andrew Rae
Woodgreen Ventures
Raza Shaikh
Raza Shaikh
Launchpad Venture Group
Justin Siemann
Justin Siemann
Sontag Foundation
Sarah Tao
Sarah Tao
CSL Behring
Martin Taylor
Martin Taylor
F-Prime Capital
Lily Ting
Lily Ting
Lundbeck
Sally Wang Liang
Sally Wang Liang
Xpanse Venture

Register for RESI Boston 2026